Hypothermia is the most potent neuroprotective therapy available. Clinical use of hypothermia is limited by technology and homeostatic mechanisms that maintain core body temperature. Recent advances in intravascular cooling catheters and successful trials of hypothermia for cardiac arrest revivified interest in hypothermia for stroke, resulting in Phase 1 clinical trials and plans for further development. Given the recent spate of neuroprotective therapy failures, we sought to clarify whether clinical trials of therapeutic hypothermia should be mounted in stroke patients. We reviewed the preclinical and early clinical trials of hypothermia for a variety of indications, the putative mechanisms for neuroprotection with hypothermia, and offer several hypotheses that remain to be tested in clinical trials. Therapeutic hypothermia is promising, but further Phase 1 and Phase 2 development efforts are needed to ensure that cooling of stroke patients is safe, before definitive efficacy trials.
Introduction
Hypothermia is recognized as the most potent putative neuroprotectant based on empirical observations and preclinical experimental data ( Fig. 1 ). Recent insights into understanding ischemia and reperfusion mechanisms suggest reasons as to why hypothermia may also be an ideal modality for extending the time window for thrombolytic stroke therapy. Although difficulties in cooling patients limited the testing of this potentially effective therapy, recent developments in technology now allow for clinical trials of therapeutic cooling for acute stroke patients. The purpose of this review is to summarize the rationale for hypothermia, the preclinical experience, and the early clinical trials. We will also discuss the advantage and limitations of surface and intravascular cooling approaches. Finally, we will pose research questions that should be addressed in the coming years.
Rationale for hypothermia in acute stroke
Interest in hypothermia for brain injury dates to anecdotal cases of children submersed under water at near-freezing temperatures for up to 40 min (1-3). However, despite decades of attempts, therapeutic hypothermia has found little use outside of the operating room (4, 5). Even in neurosurgery and cardiothoracic surgery, where hypothermia is routine, definitive evidence of efficacy is lacking from randomized, rigorously blinded, controlled clinical trials. A limited understanding of neuroprotection mechanisms limits a wider appreciation of hypothermia's therapeutic potential. Only recently have some of the mechanisms of hypothermia effect on the brain come to light.
Hypothermia causes a variety of responses in ischemic brain that might confer neuroprotection, as summarized in recent reviews (6) . No data exist to clarify the relative importance of these actions individually, but it may be simplistic to conclude that hypothermia induces several neuroprotective actions, analogous to the combinatorial neuroprotective strategy advocated by many (7, 8) . Nevertheless, if hypothermia causes multiple, synergistic effects, there is a greater potential for success in a clinical trial. Hypothermia causes significant alterations in metabolism, glutamate release and reuptake, inflammation, and free radical generation (Table 1) .
Temperature has a profound effect on brain metabolism during ischemia (9) . Intraischemic temperature changes of as little as 11C may influence outcome after focal or global brain ischemia. Initially, hypothermia was thought to protect the brain by reducing cerebral metabolism during conditions of reduced substrate; shift to anaerobic glycolysis and lactate production should be reduced (9) (10) (11) . Hypothermia decreases the cerebral metabolic rates of glucose (CMRglu) and oxygen (CMRO2) and slows ATP breakdown (reviewed by Erecinska et al. (12) ). On average, hypothermia reduces brain oxygen consumption by approximately 5%/1C fall in body temperature in the range of 22-371C (13) , and in anesthetized animals CMRO2 decreases linearly between 81C and 371C (14) . However, direct measurements of lactate showed no difference between hypo-and normothermic brains (15) .
Evolving interest in excitotoxicity yielded the observation that hypothermia markedly limited glutamate release during ischemia (16, 17) . Since hypothermia had no effect on regional cerebral blood flow (rCBF) in these trials, a protective effect was attributed to glutamate inhibition (16) . Note, however, that more severe hypothermia clearly lowers rCBF (14) . Mild hypothermia (331C brain temperature) reduced both glutamate release and hippocampal CA1 damage in a gerbil model (18) . Mild, prolonged hypothermia suppresses ischemic downregulation of the a-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor subunit GluR (2), a potentially protective effect that could rescue neurons destined to die from delayed calcium entry via AMPA receptors (19) . After cardiac arrest in rats, hypothermia significantly reduced the release of glutamate, aspartate, and GABA (20) . In marked contrast, in a gerbil forebrain ischemia model, hypothermia neuroprotection was not reversed by exogenous infusions of glutamate, suggesting that other mechanisms must also operate during hypothermia (21) .
Hypothermia prevented the increase in intracellular calcium associated with ischemia (22) (23) (24) . The mechanism of this effect is not clear, but hypothermia may impair glutamate-mediated calcium influx (19) . Hypothermia may directly inhibit calcium-mediated effects on calcium/calmodulin kinase (23) .
Hypothermia significantly reduced infarct volume and accumulation of granulocytes; upregulation of the intercellular adhesion molecule ICAM-1 was attenuated by hypothermia (25, 26) . Suppression of leukocytes was observed as late as 7 days after ischemia, even with only 2 h of hypothermia (27) . Hypothermia suppressed microglial production of toxic mediators, such as iNOS, nitric oxide, and peroxynitrite (28). Globus et al. (29) reported that intraischemic hypothermia (301C) significantly reduced the production of hydroxyl radicals whereas intraischemic hyperthermia (391C) increased the levels of these toxic reactive species. However, in some settings hypothermia may only delay granuloctye infiltration; at later time points, neutrophils and activated microglia appear in ischemic brain, and the protective effect on infarct size disappears (30) . These contradictory findings suggest that the effect of hypothermia on microcirculatory effects is complex; one possible implication is that hypothermia should be continued for very long durations, such as 24-48 h, to suppress delayed inflammatory responses to ischemia (31) .
Small alterations in intraischemic and postischemic temperature have been reported to influence early blood-brain barrier (BBB) breakdown. While mild hypothermia (331C) reduced the extravasation of a BBB tracer -horseradish peroxidase -mild hyperthermia (391C) aggravated BBB leakage compared with normothermic ischemia (371C) (32) . Because of this, hypothermia may reduce intracerebral hemorrhage after thrombolytic therapy for acute ischemic stroke, although no preclinical data exist to address this hypothesis; hypothermia could affect the risk/benefit ratio of thrombolytic therapy and allow more aggressive or delayed restoration of blood flow at a reduced hemorrhagic risk. In a rodent study, the combination of hypothermia and thrombolysis was no more beneficial than hypothermia alone (33) . Hypothermia appears Improved ischemia tolerance with hypothermia. Hypothermia was studied using a quantal bioassay in rodents (119) . The duration of occlusion for individual animals was varied to generate a range of ischemia durations for each experimental group. Behavior was rated normal/abnormal after 48 h; ratings were performed blind to treatment group. A quantal doseresponse curve was fit as a function of occlusion duration versus the 48-h behavior rating. The curve was fit by iteration, and after the best fit was found, ED 50 and its standard deviation were calculated for each treatment group. The ED 50 is the effective duration of occlusion that causes 50% of the subjects to be abnormal or dead. Two ED 50 values were compared by Student's t-test, adjusted for multiple comparisons with the Bonferroni method. Neuroprotection was demonstrated if the therapy prolonged ED 50 compared with the other groups. To explore the effect of hypothermia, groups of subjects were tested in which the temporalis temperature was kept at 36Á51C (estimated brain temperature of 37Á51C) normothermic, 341C (brain temperature 351C) hypothermic, or 381C (estimated brain temperature 391C) hyperthemic. In this experiment, hypothermia was clearly protective, compared with normo-or hyperthemic conditions (Po0Á05, Student's t-test after Bonferroni correction). to limit the release of potentially harmful matrix metalloproteinases after stroke (34) .
Other preliminary data suggest that hypothermia could have other protective effects, including reduction of free radical formation, induction of bcl-2, suppression of caspase-3 activation, and preservation of protein-kinase C activities (35, 36) . Mild hypothermia reduces the number of apoptotic appearing cells in vulnerable regions and may reduce bcl-2 expression (37, 38) . However, mild hypothermia was shown to reduce cytochrome c release, without direct effects on bcl-2 expression or caspase activation. This finding raises the hypothesis that hypothermia interrupts necrotic processes that lead to mitochondrial disruption and is unlikely to have a direct effect on the intrinsic apoptotic pathway (39) (40) (41) .
All of the above actions could interact with thrombolysis positively to improve outcomes and lengthen the time window for beginning thrombolysis. In addition, hypothermia consistently improves outcome in experimental models of temporary occlusion (see below). Hypothermia effects after permanent occlusion are less consistent. Therefore, we propose the following rationale for studying hypothermia in human stroke and for combining hypothermia with thrombolysis: A. Cooling may reduce neuronal damage from excitotoxins, inflammation, free radicals, and apoptosis, preserving neurons until reperfusion occurs. Later (3-6 h) thrombolysis could prove effective, because more salvageable neurons will be present in the ischemic zone. B. Cooling may reduce the microcirculatory response to ischemia, minimizing granulocyte infiltration and microglial activation. This could manifest as improved outcome, reduced ischemic-edema, or a lower risk of post-reperfusion hemorrhage.
Definitions
The literature offers no consistent definitions of hypo-, normo-, and hyperthermia. To compound confusion, there is no uniformity with respect to measurement site: core body tem-'perature may differ from skull surface and both may differ from deep brain temperature. Generally, temperatures between 321C and 351C are considered mild hypothermia, and temperatures below 251C are labeled deep hypothermia. Inconsistently applied terms for temperatures between 251C and 321C include moderate, clinical, and surgical hypothermia.
Thermoregulatory control
A highly effective thermoregulatory system controls core body temperature tightly near 371C. Effective thermoregulatory control requires thermal sensing (skin), central regulation, and regulated autonomic responses to defend core temperature. Warm responses (sweating and active vasodilatation) are triggered at a threshold temperature only 0Á21C greater than that for the first cold defense (vasoconstriction). Thermoregulatory defenses are triggered by temperatures outside this range, so that core body temperature is typically controlled within 0Á21C of the set-point. Thermoregulatory thresholds are affected by age but not by body type or gender (42, 43) .
Defenses against cooling include cutaneous vasoconstriction and shivering. Cutaneous vasoconstriction occurs in arteriovenous shunts located primarily in the fingers and toes (44) . These shunts are controlled by centrally mediated a-1 adrenergic receptors; however, constriction may be augmented during local hypothermia via a-2 adrenergic receptors. Shivering produces heat through the repetitive contractions of agonist and antagonist muscles. The only mechanism that increases metabolic heat production in humans is shivering because humans do not utilize non-shivering thermogenesis (45, 46) .
Numerous drugs alter thermoregulatory control, including most anesthetics and narcotics. Drugs inhibit thermoregulation roughly in proportion to their anesthetic properties, but the central nervous system centers involved in this effect are unknown. Thus, the volatile anesthetics and propofol inhibit thermoregulation far more than opioids, which, in turn, are more effective than minor sedatives (47) (48) (49) . Meperidine is the most important and clinically relevant drug to inhibit thermoregulatory responses. The antishivering action of meperidine decreases the shivering threshold twice as fast as the vasoconstriction threshold (Fig. 2) .
Meperidine is highly effective at eliminating shivering, although the mechanism is unknown (50, 51) . Twenty-five milligrams of meperidine (i.v.) decreases the shivering thres- 
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hold by 21C with no effect on alertness or respiratory function (51) . Large-dose meperidine causes substantial sedation and respiratory depression; combining other agents with meperidine may allow a greater antishivering effect with less sedation and respiratory depression. Recently, for example, large-dose buspirone reduced the shivering threshold to 35Á070Á81C whereas large-dose meperidine reduced the shivering threshold to 33Á470Á31C (52) . The threshold during the combination of small doses of the two drugs was 33Á470Á71C. There was only minimal sedation noted with the buspirone and combination of meperidine and buspirone. End-tidal PCO 2 increased by 10 mmHg with meperidine alone. The combination of small-dose buspirone and small-dose meperidine acts synergistically to reduce the shivering threshold while causing only minimal sedation or respiratory depression. It is not known why the combination of buspirone and meperidine acts synergistically rather than additively. Buspirone produces hypothermia in rats because it is a 5-HT 1A partial agonist (53, 54) . 5-HT produces hyperthermia in cats but produces hypothermia in numerous other species (55, 56) . Additive, but not synergistic, effects were seen with the combination of meperidine and dexmedetomidine (47), a highly selective and potent a-2 agonist. Recent clinical work suggests that dexmedetomidine has only mild sedative effects with only minor blood pressure depression and no respiratory depression in doses that significantly inhibit thermoregulatory responses (57) .
Hypothermia and acute ischemic stroke
Review of preclinical studies Therapeutic hypothermia after permanent middle cerebral artery occlusion (MCAo) shows limited promise. Infarct volume after MCAo was reduced with 6 h deep hypothermia (temporalis temperature o241C) (58) . As little as 1-h hypothermia benefited animals with permanent MCAo (59) . The hypothermia could be delayed up to 1 h after permanent MCAo and still be effective, but no benefit was seen if hypothermia was delayed 2 or 3 h (60). In contrast, others have found no protective effect after permanent MCAo with hypothermia (61, 62) . There is no obvious explanation for the divergent results.
After temporary MCAo, hypothermia consistently shows protective effects (Fig. 1) . The University of Miami group compared permanent and temporary (2-h clip) occlusion directly, in rats, and showed greater benefit in the temporary occlusion group (61) . Similarly, spontaneously hypertensive rats (SHR) subjected to 1-h MCAo (direct ligature) were protected by lowering temperature to 331C during ischemia and 1 h of reperfusion (62) . Spontaneously hypertensive rats subjected to 80 min MCAo were benefited by intraischemic brain temperatures to 321C, whereas 291C completely prevented infarction (63) . No benefit accrued after permanent MCAo. The Henry Ford group also showed impressive neu-roprotection with intraischemic hypothermia begun during a 2-h MCAo (intraluminal suture) (64) and after hypothermia delayed up to 3 h (65). Sprague-Dawley rats subjected to 2-h MCAo by clip plus bilateral ICA occlusion, treated with 3 or 22 h of hypothermia, were significantly benefited (66); the longer duration of hypothermia appeared to be more beneficial. Relevant to future clinical trials, the 22-h rats were rewarmed to normothermia over 24 h to avoid rebound hyperthermia. Using the same treatment paradigm, benefit was noted after permanent MCAo as well, and no effect on rCBF was noted (67) .
Hypothermia to 321C for 2 h after MCAo ameliorated magnetic resonance measures of brain edema associated with ischemia; there were no perfusion effects noted (68) . Another group confirmed these magnetic resonance imaging benefits, and added the observation that hypothermia reduced stressresponse gene induction (69) . In a similar model, hypothermia exhibited a highly protective effect on behavioral measures, including a neuro-score (70) . Postischemic cooling ameliorated behavioral deficits and infarct volumes as effectively as intraischemic cooling in Sprague-Dawley rats given 2-h MCAo (71, 72) .
A delay to cooling from ischemia onset, 2Á5 h, was obtained in SHR given 90-min MCAo; outcome was assessed with a behavioral task and infarct size (73) . Hypothermia was continued for 24 h and temperature control was used to avoid rebound hyperthermia for another 24 h: hypothermia significantly improved all outcome measures. In contrast, 2 h of hypothermia to 331C conferred benefits in behavioral and histological measures when delayed up to 120 but not 180 min, after MCAo onset (71) .
The benefits of hypothermia persist to longer observation times. Infarct volumes 30 days following stroke were reduced in hypothermia-treated subjects, compared with controls (66). Mild, prolonged hypothermia after 90 min MCAo prevented behavioral impairment 30 days after stroke (73) . This longterm behavioral benefit was associated with infarct volume reduction. Similar results were obtained in another laboratory, with behavioral and histopathological protection documented 60 days after temporary MCAo (71) .
It is not clear from the available data what the most appropriate target temperature is, but small differences in brain temperature critically impact outcome (74) . As little as 21C brain cooling significantly protected the hippocampus during transient forebrain ischemia, as did cooling the core temperature to 341C (75) (76) (77) . In a permanent MCAo model, immediate cooling to 301C, 331C, or 34Á51C was equally effective (78) . On the other hand, cooling the intraischemic brain temperature to 291C proved superior to 341C, which was superior to normothermic controls (63) .
In summary, hypothermia to 33-351C is effective therapy for focal cerebral ischemia. Optimal results accrue if treatment begins during ischemia, but therapy can be delayed for 2 or 3 h after ischemia onset and still provide benefit, especially if cooling is continued for long durations and the subject is gradually rewarmed (73, 31) . There are insufficient data to determine the appropriate depth of hypothermia; 351C may be as effective as 331C. The optimum duration of hypothermia treatment and the optimum rewarm period have not been determined.
Global ischemia
Global ischemia models are used to cause a reproducible zone of ischemia in the rodent or gerbil forebrain. Methods include bilateral carotid occlusion with hypotension (2-VO) or ligation of both vertebral arteries and transient occlusion of both carotids, with or without hypotension (4-VO). While these models do not cause zero-level rCBF, they do cause reproducible injury to the hippocampus bilaterally, enabling elegant and powerful histological measurements. There is also a characteristic learning impairment.
Ikonomidou et al. (79) demonstrated protective effects of hypothermia in rat pups given hypoxia and unilateral carotid occlusion. Axillary temperatures of 291C or 321C protected the cortex and hippocampus. In a 2-VO model, post-ischemic hypothermia begun 5 but not 30 min after release of the carotid ligatures resulted in preserved hippocampal CA1 sector neurons. Using a 2-VO gerbil model, hypothermia (rectal temperature 34Á51C) for 8 h blocked damage to the CA1 neurons and improved survival (80) . Similar results were obtained with hypothermia begun before ischemia: 35Á51C was effective and 32Á51C completely blocked histological damage from ischemia (81) . Mild hypothermia (rectal temperature 341C) for 2 h protected 2-VO rats after 8 but not 12 min (75). After 5 min 2-VO in gerbils, neither 331C nor 381C was effective if used for 1 h after ischemia (82) . Intraischemic hypothermia during 12Á5 min 4-VO in rats prevented histopathological damage and behavioral sequelae (83) .
To assess the time window and explore the needed duration of hypothermia, the gerbil 2-VO model was used (84) . Intraischemic hypothermia (rectal temperature 28-321C) completely prevented hippocampal cell damage if continued for 4 or 6 h; 2 h of hypothermia protected less well, and 1 or 0Á5 h protected not at all. The 6-h duration was studied further by delaying the onset of therapy: hypothermia begun immediately or 1 h after ischemia was very protective; delay to 3 h erased the benefit. Similar studies, using the rat 2-VO, also confirmed that postischemic hypothermia to 301C (brain temperature) was not as effective as intraischemic hypothermia (85) .
Further extensions of the treatment window were attempted with longer durations of hypothermia (86) . In 2-VO gerbils, brain temperatures were maintained at 321C or 341C for 24 h after ischemia. Whether hypothermia was delayed 1 or 4 h after ischemia, behavioral deficits were ameliorated and CA1 neuron counts were partially protected: the 1-h delay animals did better than the 4-h delay animals. These benefits were recorded 6 months after ischemia, suggesting that hypothermia conferred long-term effects on behavior and hippocampal mor-phology. In rats, identical phenomena were noted: 4-VO ischemia for 10 min was treated with 24-h hypothermia (321C brain temperature) that was initiated 6 h after the ischemia (87); injury to the hippocampus was markedly attenuated at 7 or 28 days survival, suggesting lasting neuroprotection.
In summary, hypothermia appears to be neuroprotective in some, but not all, forebrain ischemia models. The disparate results are most likely due to differences in the therapeutic window (delay to initiation), depth, and duration of hypothermia. There are also differences in temperature assessments, with some studies using brain and others using external (scalp, rectal) measurements. In Colbourne's; laboratory, where the cooling paradigm most closely resembles clinical settings, longer ischemia durations seem to protect after delays as long as 6 h. Colbourne et al. (87) compared hypothermia to other agents, and asserts that hypothermia is more effective than any other treatment class.
Review of clinical studies
Occasionally, children and some adults emerge from near drowning in ice-cold water free of neurologic sequelae, prompting an interest in hypothermia as therapy (2, 3). Clinical use of hypothermia began in earnest in the 1940s in patients with head injuries. In short order it became apparent that awake patients do not tolerate hypothermia, and the widest application of hypothermia has been in the operating room (4). Recent clinical trials of hypothermia for head trauma have shown mixed results (88) (89) (90) .
Preliminary human studies showed that mild postischemic hypothermia might be effective in improving neurologic outcome after cardiac arrest (91) (92) (93) (94) (95) . These early positive experiences culminated in two randomized, controlled trials, likely to change medical practice in cardiopulmonary resuscitation. The first study, by the European group 'The Hypothermia After Cardiac Arrest (HACA) Study Group', randomly assigned patients suffering from ventricular fibrillation (VF) cardiac arrest to either a hypothermia (n 5 137) or a normothermia group (n 5 138) (94) . Patients in both groups were treated identically, except that the patients in the hypothermia group were cooled to a target of 32-341C. The median time to initiation of cooling was 105 min, and the time from initiation to arrival at the target temperature was 8 h. Outcomes were assessed at 6 months. There was a statistically significant increase in the survival rate (59% vs. 45%) and the rate of favorable neurologic outcome (55% vs. 39%) favoring the hypothermia group over the control group. The second study, by the Australian group headed by Bernard et al. (92) , studied the effect of moderate hypothermia (331C) on patients who remained comatose after resuscitation from out-of-hospital VF cardiac arrest (92) . Eighty-six patients were enrolled and randomly assigned to the hypothermia or normothermia group. In contrast to the HACA trial, hypothermia was initiated in the preclinical setting; therefore, the hypothermia group reached their target temperature earlier, approximately 120 min after the return of spontaneous circulation. Of the cooled patients, 49% survived with good neurological outcome (discharged home or to a rehabilitation facility), compared with 26% of the normothermia group (P 5 0Á046). These two trials show that delayed, mild hypothermia improves mortality and neurologic outcome in patients who suffer cardiac arrest.
Pilot studies of hypothermia for stroke have been published. Schwab et al. (96) studied the effects of moderate hypothermia in 25 patients with severe hemispheric ischemic brain infarcts. Hypothermia to 331C for 48 to 72 h was induced 1477 h after stroke onset using skin surface cooling techniques. Intracranial pressure (ICP), cerebral perfusion pressure, and brain temperature were continuously monitored. Neurological outcome was analyzed at 4 weeks and 3 months after the stroke via the Scandinavian Stroke Scale (SSS) and Barthel Index (BI). The data showed a reduction in mortality and an increase in the proportion of patients with a favorable outcome (BI470) as compared with historical controls. The authors also found that elevated ICP values could be significantly reduced during hypothermia.
In a similar study of deeper hypothermia, to 321C, ICP was significantly reduced after massive infarction (97) . However, side-effects included thrombocytopenia, bradycardia, pneumonia, pancreatitis, hypotension, severe coagulopathy, and cardiac failure. In addition, moderate hypotension was noted in most patients, and hypokalemia in all patients, but only five required potassium replacement. It appears that 331C may be the lowest feasible core temperature in stroke patients, but this point should be studied further.
In the Copenhagen Stroke Study, 17 patients were cooled with a forced air cooling blanket and compared with 56 nonrandomized controls (98) . Intravenous meperidine was used to prevent shivering in these awake patients. The group mean tympanic temperature reached 35Á51C after 5 h of cooling, which was discontinued after 6 h; patients gradually rewarmed spontaneously over 6 more hours. As might be expected in stroke patients, there were significant serum marker changes over 6 h that were all consistent with slight hemoconcentration. Clotting factors and coagulation times did not change, nor were there any other adverse events associated with the cooling, such as cardiac arrhythmias or infections. No beneficial effects on outcome measures could be detected in this small study.
The COOLing for Acute Ischemic brain Damage (COOL AID) study included 10 patients and 9 non-randomized controls; the patients were cooled with blanket and alcohol rubs after paralysis, intubation, ventilation, and narcotic infusion (99) . In this trial, patients received thrombolysis up to 3 h after stroke and hypothermia began up to 6 h after stroke; hypothermia continued for 48 h. Serial transcranial Doppler was used to observe recanalization, and hypothermia was continued for only 12 h after recanalization was documented; the maximum period of cooling was 72 h. On average, cooling to target temperature required 3Á5 h, but in 9 of 10 patients there was an overshoot to cooler temperatures. The hypothermia seemed to be well tolerated with few complications, although only the treated, and none of the control patients, were paralyzed and intubated. Sinus bradycardia was noted more often in the treated patients and one required a temporary pacemaker; this patient suffered massive stroke because of aortic dissection and therefore the etiology of the bradycardia is unclear. No benefit on outcome measures could be detected.
Endovascular cooling has been shown to be feasible in two trials (100, 101) . The second COOL AID trial demonstrated safety and feasibility of endovascular cooling in 18 patients compared with 22 controls in a randomized trial. Thirteen patients reached a target temperature of 331C in about 80 min, but five patients did not reach the target. Complications included hemorraghic transformation in two of the cooled patients, but other complications including deep vein thrombosis and pulmonary edema occurred in both groups. The ICTuS trial compared various antishivering regimens in 18 patients, all of whom were cooled. The target was reached only in patients who received a proactive antishivering regimen consisting of intravenous meperidine, oral buspirone, and a surface warming blanket. The proactive regimen is currently being tested in a Phase 2 trial. There were three hemorrhagic transformations in the ICTuS patients.
Surface cooling was shown to be feasible in two trials (102, 103) . In young healthy volunteers, surface cooling could be induced and maintained; shivering was suppressed with intravenous meperidine and chlorpromazine (102) . In a variety of ICU patients, surface cooling effectively controlled fever, but therapeutic hypothermia was not attempted (103) .
In summary, pilot clinical experience suggests that hypothermia is feasible in acute stroke patients using surface cooling methods. There seems to be a delay in reaching the target temperature of a few hours. Anesthetized patients have tolerated hypothermia as long as 72 h, but few awake patients have been treated. Previously, cooling required general anesthesia, including paralysis, intubation, and narcotic infusion, although the 17 patients in the Copenhagen study tolerated surface cooling to a core temperature of 35Á51C. Deeper hypothermia would probably require paralysis and ventilation. In recent pilot studies, awake stroke patients tolerated mild hypothermia.
Logistical issues

Surface versus internal cooling
Surface cooling methods include convective air blankets, water mattresses, alcohol bathing, and ice packing. Surface cooling strategies have been limited by a slow rate of temperature change, target temperature overshoot, poor control at the target temperature, and cumbersome administration. Awake patients report discomfort during rapid skin and surface cooling, although intravenous meperidine seems to limit this (103) . Two phenomena limit cooling rate during surface hypothermia: skin vasoconstriction with subsequent redistribution of blood flow to the core, which limits heat exchange, and shivering (104) . With surface cooling, it can be very difficult to control target temperature precisely; target temperature overshoot was observed in 9 of 10 patients in the COOL AID study (99) . During excessive cooling (core temperature below 331C), there is an increased risk of cardiac and other complications. However, further studies of surface methods are ongoing, and in young volunteers (average age 30 years) tight control was demonstrated (102) .
To overcome the problems with surface cooling and other techniques, several groups proposed intravascular cooling (105) . Internal -or intravascular -cooling allows simultaneous surface warming to reduce shivering by altering the thermoregulatory set-point. Chilled saline infusions promote the rapid reduction of core temperatures in anesthetized patients, but require large infusion volumes (106) . Alternatively, heat exchange devices can be placed in the blood stream, but in the past such cooling devices were associated with increased risk of thrombosis. Recently, new materials have incorporated antithrombotics onto the surface of the catheter; indwelling heat transfer devices can be implanted for several hours or days without inducing thrombosis (107, 108) . Three such devices have been used in preliminary safety trials to cool patients internally. Cooling rates of 1Á470Á61C/h have been observed using these devices, compared with surface cooling (105) . Patient comfort is greater under the warming blanket and the influence of modest meperidine doses.
Therapeutic hypothermia -whether by surface or intravascular methods -would seem to depend on restoration of blood flow to the ischemic territory. It is not known to what extent heat transfer can occur in the non-reperfused brain. Further, it is not clear whether heat generated or removed from extracerebral structures (skull, scalp) influences significantly heat content within the skull. If significant quantities of heat do transfer from the non-reperfused brain to the skull and scalp, then topical head cooling could potentially prove beneficial. Body surface cooling would depend on intact cerebral circulation to the same extent as intravascular cooling, because heat would have to move from brain to blood, and finally to skin.
Effect of hypothermia on thrombolysis
In vitro, the recombinant tissue-type plasminogen activator (rt-PA) effect on clot lysis is temperature dependent. Cooling to 30-331C caused a 2-4% decrease in t-PA activity in a clot lysis assay (109) . Data available from the manufacturer (Genentech, South San Francisco, CA) indicated that t-PA activity decreases by 50% when the clot temperature drops from 401C to 301C. This finding was confirmed independently (110) . These data must be interpreted with caution, however, because hypothermia suppresses all aspects of the clotting cascade and fibrinolytic pathways, including thrombolytic inhibitors; hypothermia suppresses platelets and may limit platelet reaggre-gation in the microcirculation (111) . No clinical stroke studies are available to address the effect of hypothermia on t-PA efficacy directly. In trauma patients who were hypothermic, the net effect of hypothermia was a slight increase in propensity toward clotting and no net effect on fibrinolysis (112) . Another trial of moderate hypothermia (32-331C) after head trauma showed no effect on clotting studies or the incidence of delayed intracerebral hemorrhage (113) . Of relevance to stroke, these patients were hypothermic for 24 h, and rewarmed over 12 h; coagulation studies were assayed before therapy and 24 h later. In the absence of better data, there is no obvious contraindication to the combination of thrombolysis and hypothermia, but thrombolytic activity may be decreased by 4% to 20% (114) . It remains to be shown whether hypothermia reduces hemorrhagic complications by minimizing the activities of matrix metalloproteinases after ischemia (115, 114) .
Time window and duration of hypothermia
Although earlier treatment is likely better than later, the time parameters that optimize the effects of hypothermia remain elusive. In the setting of ischemic stroke, animal studies clearly demonstrate that it is best to institute cooling intraischemically. Fortunately, beneficial effects have also been demonstrated if mild to moderate hypothermia is initiated in the immediate or early postischemic period. Animal studies suggest that the earlier the onset of cooling, the shorter the cooling duration to confer benefit (73, 31) . However, the effective therapeutic window for hypothermia in human stroke is not known. The same holds true with duration of treatment: longer postischemic duration is likely to be more effective, although the optimal duration of treatment remains unknown.
During intravenous thrombolysis, complete recanalization is the exception rather than the rule; adjunct hypothermia started within 3 h is likely intra-rather than postischemic (116) . In patients treated with i.v.-rt-PA, the rate of recanalization varied between 25% for terminus internal carotid artery (ICA) occlusions and 60% for basilar occlusions (116) . Future studies of hypothermia, therefore, should aim to begin cooling shortly after the rt-PA infusion. After recanalization, reocclusion may occur in up to 34% of patients with any initial recanalization (117) . Cooling patients after recanalization therefore could be protective in the event of reocclusion.
Questions and considerations for future trials
Newly developed intravascular cooling devices appear attractive, compared with surface cooling methods. It is not clear, however, whether such devices are truly safe, despite promising pilot studies. Considerable further work in elderly stroke patients is needed; complication rates in more typical stroke populations may be higher than those we have observed to date. Surface cooling has the considerable advantage of prehospital feasibility.
As of this writing, therapeutic hypothermia stroke protocols all use 331C as the target depth temperature (Table 2) . Based on preclinical work, 331C seems to be effective, and so far this target appears to be well tolerated by awake patients if surface warming and meperidine are used. If further pilot work shows promise, comparison trials must be designed to determine whether lesser depths would be as effective: as little as 351C was effective in some animal models, and this hypothermia level must be compared with 331C eventually. In contrast, it may be that greater depths of hypothermia, despite the side-effects, may prove more protective. For the moment, until hypothermia is conclusively demonstrated to be neuroprotective, the most appropriate target temperature seems to be 331C.
No consensus exists as to the hypothermia duration required after stroke. In Colbourne's laboratory, hypothermia duration based on stroke severity proved highly effective and feasible. If hypothermia proves effective in Phase 2 trials, additional comparisons, varying the duration, should be conducted. Duration could easily be driven by baseline stroke severity, using a stroke scale or lesion volume measurement.
Few data are available to guide the duration of the rewarm period. Limited experience suggests that rebound ICP elevations occur after cooling massive strokes (97). Current consensus calls for 12 or 24 h of gradual rewarming. Eventually, trials should attempt to identify the optimum rewarm time. On the other hand, there should also be emphasis on finding a non-invasive marker that might guide the rewarm rate in individual patients.
The therapeutic temporal window for hypothermia is unknown. Based on our limited understanding of the mechanisms, one could speculate that later onset of hypothermiaup to 12 h after stroke onset -could be effective. Yet preclinical trials justify only a 3-6-h window. For the moment, investigation should focus on the earliest possible window, to yield the greatest possible chance of showing benefits if they exist. Once benefit is conclusively documented, then the window could be extended. In particular, there may be considerable value in extending the window for thrombolysis with hypothermia.
Considerable improvements in the antishivering protocol are expected. At this time, meperidine and buspirone seem quite reasonable choices, especially in combination with surface warming. More effective blocking agents should be developed, with emphasis on minimizing respiratory suppression and other side-effects. Preliminary and anecdotal reports indicate that warming only the hands and face could be as effective as warming the entire body at resetting the thermoregulatory setpoint (118) . These reports should be followed with careful, rigorous comparisons, because the heat transfer associated with warming blankets counteracts the cooling catheter.
Final, definitive evidence of efficacy will require a large Phase 3 clinical trial. State-of-the-art clinical trial design incorporates thrombolysis. Hypothermia may prove synergistic in benefit with thrombolysis, because hypothermia consistently proves more effective in temporary, compared with permanent, occlusion models. A trial that incorporates two therapies is awkward, however, and necessarily larger than trials of single agents. Despite the complexity, however, it seems wise to approach stroke therapy with combination therapy; sufficient numbers of attempts at monotherapy have failed to support this notion. The parameters for using stroke hypothermia are listed. The range column shows the range of values for each parameter that either have been studied or are under consideration at the time of this writing. Depth refers to the hypothermia depth in degrees Celsius; listed is the range of possible target temperatures. Duration refers to the length of time to keep the stroke patient at the depth (target) temperature. Window refers to the maximum time after stroke onset that hypothermia could be begun and still prove effective. The window for thrombolysis currently is 3 h; for hypothermia, trials have used a window as long as 12 h. In preclinical trials, 2 h proved to be the maximum treatment window in some studies. Rewarm refers to the amount of time required to raise the core temperature from the target to 37Á51C. Faster cooling rates are anecdotally associated with rebound intracranial pressure elevations in patients with larger strokes. Thrombolysis refers to the combination of hypothermia with thrombolysis.I.v., intravenous; IA, intra-arterial.
